Gerresheimer (XTRA:GXI) Valuation Reset After Accounting Issues And Potential €240 Million Write Downs

Simply Wall St

Mon, February 16, 2026 at 2:07 AM GMT+9 3 min read

In this article:

GRRMF

0.00%

GRRMY

+13.87%

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Why Gerresheimer (XTRA:GXI) is Under Intense Scrutiny Right Now

Gerresheimer (XTRA:GXI) has come under pressure after disclosing accounting issues around revenue recognition and inventory valuation, with potential write downs of €220 million to €240 million and a delay to its 2024 financial statements.

See our latest analysis for Gerresheimer.

The accounting investigation and potential €220 million to €240 million write downs have clearly shifted risk perceptions, with a 7 day share price return of negative 22.49% and a 1 year total shareholder return decline of 74.67%, pointing to fading momentum despite a recent 4.52% 1 day share price rebound to €19.89.

If this accounting shock has you reassessing risk, it could be a good moment to look at our list of 102 top founder-led companies as fresh ideas for further research.

With the share price down sharply over 1 year and the stock trading at a sizeable discount to both analyst price targets and some intrinsic estimates, you have to ask: is this a reset buying opportunity, or is the market correctly pricing in future challenges?

Most Popular Narrative: 41.8% Undervalued

Gerresheimer’s most followed narrative points to a fair value of €34.17 per share, well above the last close at €19.89, which puts the recent sell off into sharper focus.

The acquisition of Bormioli Pharma is expected to propel Gerresheimer’s revenues from €2 billion in 2024 to around €2.5 billion in 2025, while also enhancing the company’s adjusted EBITDA margin to approximately 22%. This marks a significant step forward in terms of revenue growth and profitability enhancement.

Read the complete narrative.

Want to see what sits behind that higher fair value? The narrative leans on rising earnings, firmer margins and a future profit multiple that assumes investors stay confident. Curious which specific profit and growth assumptions need to hold up to reach that outcome? Read on in the full narrative to see how each piece fits together.

The fair value estimate of €34.17 is built using a 10.19% discount rate, applied to analysts’ expectations for revenue growth, margin improvement and future earnings up to around 2028. In simple terms, the model projects future profits, then discounts them back to today using that higher required return, and applies a future P/E multiple of 13.63x to those expected earnings to anchor the end point.

Importantly, this narrative also assumes Gerresheimer continues to grow its top line and lift profit margins from current levels, while keeping the number of shares roughly flat. Those ingredients together support the view that today’s price embeds a large gap to the earnings power analysts expect the business to reach over the coming years.

Story Continues  

Result: Fair Value of €34.17 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this hinges on Bormioli being integrated smoothly and on higher leverage staying manageable, as any missteps here could quickly challenge the upbeat fair value story.

Find out about the key risks to this Gerresheimer narrative.

Build Your Own Gerresheimer Narrative

If some of these assumptions do not sit right with you, or you would rather test your own view using the same data, you can build a personalised Gerresheimer thesis in just a few minutes and Do it your way.

A great starting point for your Gerresheimer research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Gerresheimer is only one part of your watchlist, this is a good moment to widen the net and compare your thinking with other opportunities.

Scan for potential bargains with robust fundamentals by running our 229 high quality undervalued stocks and see which companies stand out on quality and pricing.

Prioritise resilience by checking companies that score well on debt and liquidity in the solid balance sheet and fundamentals stocks screener (371 results), so fragile balance sheets do not catch you off guard.

Lock in income ideas by reviewing the 437 dividend fortresses and see which names combine higher yields with a focus on stability.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include GXI.DE.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info